Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, ...

Clearmind has 28 granted patents across 18 patent families, with patents granted in major jurisdictions. Clearmind shares are trading higher Friday after the company announced advancement in its ...

Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, ...

The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial Vancouver, Canada, March 04, 2026 (GLOBE ...

Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, ...

Clearmind Medicine (NASDAQ: CMND) stock is up 60% this morning. This does not make up for the 58% fall a couple of weeks back, that's not how percentages work. But the CMND stock price is, at least, ...

Clearmind Medicine (NASDAQ: CMND) has risen 65% premarket this morning - and on good trade too, 5 million shares - off the back of a story about having made a patent application. We struggle to see ...

Study represents the first clinical application of CMND-100, the Company’s proprietary drug platform “Transitioning to a clinical stage pharmaceutical company is a major milestone for our Company, ...

VANCOUVER, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of ...

FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the ...